UK markets open in 44 minutes
  • NIKKEI 225

    29,682.83
    -156.88 (-0.53%)
     
  • HANG SENG

    24,221.54
    +122.40 (+0.51%)
     
  • CRUDE OIL

    70.51
    -0.05 (-0.07%)
     
  • GOLD FUTURES

    1,779.30
    +1.10 (+0.06%)
     
  • DOW

    33,919.84
    -50.63 (-0.15%)
     
  • BTC-GBP

    30,746.93
    -705.41 (-2.24%)
     
  • CMC Crypto 200

    1,038.78
    -25.07 (-2.36%)
     
  • ^IXIC

    14,746.40
    +32.49 (+0.22%)
     
  • ^FTAS

    4,029.01
    +42.11 (+1.06%)
     

Kintor Pharma Announces the Primary Endpoint of Phase II Clinical Study for KX-826's Treatment of Androgenetic Alopecia Was Met

·2-min read


EQS-News / 09/09/2021 / 10:09 UTC+8

Kintor Pharma Announces the Primary Endpoint of Phase II Clinical Study for KX-826's Treatment of Androgenetic Alopecia Was Met

 

Suzhou, September 8, 2021 - Kintor Pharmaceutical Limited ("Kintor Pharma", HKEX:9939), a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, today announced the primary endpoint of phase II clinical trial of  pyrilutamide ("KX-826", tincture) in China for the treatment of androgenetic alopecia (AGA) was met, which was statistically significant and clinically meaningful.

 

The phase II clinical trial was a multicenter, randomized, double-blinded, placebo-controlled study to assess the efficacy and safety of KX-826 for the treatment of male AGA adults (N=120). The primary endpoint for the trial was the change from baseline in non-vellus target area hair counts (TAHC) at week 24 in comparison with placebo. 

 

The majority of adverse events (AEs) were mild and no serious adverse event (SAE) was reported. KX-826 was well-tolerated and no new safety signals were observed. Detailed data will be released later upon the finalization of the clinical study report. 5mg (0.5%) KX-826 was determined as the dose to be taken into phase III clinical trial in China, which we expect to kick off the work in Q4 2021.

 

Dr. Youzhi Tong, Founder, Chairman, and CEO of Kintor Pharma, commented, "We are delighted to see the primary endpoint in KX-826's phase II study for AGA was met. Hundreds of millions of people around the world are troubled with AGA, accounting for approximately 90% of patients with hair loss. There is an urgent need for a safer and more effective drug to address this problem. We are conducting phase II clinical trial of KX-826 for the treatment of male AGA patients in the US and will accelerate the progress of phase III clinical trial of KX-826 for the treatment of male AGA patients in China. We also target to conduct phase II clinical trial for female AGA patients in China, so as to bring benefits to the people suffering from AGA around the globe as soon as possible."

 

About Kintor Pharmaceutical Limited

Kintor Pharmaceutical Limited is developing and commercializing a robust pipeline of small molecule and biological drugs for androgen-receptor-related disease areas with unmet medical needs, including COVID-19, prostate, breast and liver cancer, alopecia and acne. For more information, visit www.kintor.com.cn.

 

09/09/2021 Dissemination of a Marketing Press Release, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.

Media archive at www.todayir.com

show this
show this
Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting